Superworth

Halozyme Therapeutics price to sales ratio HALO

Market value divided by revenue over the last twelve months, since 2012.

Today, Nov 2, 2026
8.8×
10-year median
10.2×
Against its 10-year history
45th
percentile: 0 is its lowest day, 100 its highest
10-year range
5.2× to 33.8×
Peer median
6.8×

Halozyme Therapeutics' price to sales ratio is 8.8× as of Nov 2, 2026.

That is below its ten-year median of 10.2×, close to the middle of its last ten years.

Over that time it ranged from 5.2× in Mar 2026 to 33.8× in Feb 2021.

The median for 10 biotech stocks of a similar size is 6.8×.

Price to sales ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far8.8×5.2×8.9×
20256.5×5.9×7.9×
20246.5×5.7×9.3×
20236.3×5.7×12.9×
202213.3×9.9×15.1×
202112.2×9.9×33.8×
202028.9×11.0×29.1×
201913.0×7.6×16.8×
20187.3×7.1×17.5×
201717.4×9.2×18.8×
20168.0×6.9×16.8×
201519.6×1.7×38.3×
201421.0×16.3×31.3×
201327.1×13.8×40.8×
201232.7×9.3×34.4×

Against its peers

Companies in Biotechnology nearest Halozyme Therapeutics' size, closest first, today.

CompanyPrice to sales ratio
HALOHalozyme Therapeutics8.8×
NBIXNeurocrine Biosciences4.4×
EXELExelixis7.1×
TECHBIO-TECHNE9.4×
ALNYAlnylam Pharmaceuticals4.4×
RGENRepligen12.4×
INCYIncyte4.2×
KRYSKrystal Biotech19.9×
UTHRUnited Therapeutics8.2×
ONCBeOne Medicines6.6×
ADMAAdma Biologics4.8×
Peer median6.8×

Where Halozyme Therapeutics ranks

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Halozyme Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.